Diazoxide

From Wikipedia, the free encyclopedia

Template:Short description Template:DMCA Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Diazoxide
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesProglycem, others
AHFS/Drugs.comMonograph
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: C
Routes of
administration		By mouth, intravenous
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Protein binding90%
MetabolismLiver oxidation and sulfate conjugation
Elimination half-life21-45 hours
ExcretionKidney
Identifiers
  • 7-Chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC8H7ClN2O2S
Molar mass230.67 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Melting point330 to 331 °C (626 to 628 °F)
  • Clc1ccc2c(c1)S(=O)(=O)/N=C(\N2)C
  • InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11) checkY
  • Key:GDLBFKVLRPITMI-UHFFFAOYSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Diazoxide, sold under the brand name Proglycem among others, is a medication used to treat low blood sugar due to a number of specific causes.[4] This includes islet cell tumors that cannot be removed and leucine sensitivity.[4] It can also be used in refractory cases of sulfonylurea toxicity.[5] It is taken by mouth.[4]

Diazoxide, used as the salt diazoxide choline, and sold under the brand name Vykat XR, is used for the treatment of hyperphagia in people with Prader–Willi syndrome.[3] It was approved for this use in the United States in March 2025.[6]

Common side effects include high blood sugar, fluid retention, low blood platelets, a fast heart rate, increased hair growth, and nausea.[4] Other severe side effects include pulmonary hypertension and heart failure.[4] It is chemically similar to thiazide diuretics.[4] It works by decreasing insulin release from the pancreas and increasing glucose release by the liver.[4]

Diazoxide was approved for medical use in the United States in 1973.[4] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[8]

Medical uses

Diazoxide is used as a vasodilator in the treatment of acute hypertension or malignant hypertension.[9]

Diazoxide also inhibits the secretion of insulin by opening ATP-sensitive potassium channel of beta cells of the pancreas; thus, it is used to counter hypoglycemia in disease states such as insulinoma (a tumor producing insulin)[10] or congenital hyperinsulinism.

Diazoxide acts as a positive allosteric modulator of the AMPA and kainate receptors, suggesting potential application as a cognitive enhancer.[11]

Side effects

Diazoxide interferes with insulin release through its action on potassium channels.[12] Diazoxide is one of the most potent openers of the K+ ATP channels present on the insulin producing beta cells of the pancreas. Opening these channels leads to hyperpolarization of cell membrane, a decrease in calcium influx, and a subsequently reduced release of insulin.[5]

The US Food and Drug Administration (FDA) published a safety announcement in July 2015 highlighting the potential for development of pulmonary hypertension in newborns and infants treated with this drug.[13]

Diazoxide has been associated with development of hypertrichosis and stimulation of scalp hair growth.[14][15]

Research

Under the name Vykat XR, diazoxide choline is an approved therapy forPrader-Willi syndrome[3][16][17][18] and is under investigation for monogenic obesity caused by mutations in the SH2B1, PCSK1, or SIM1 genes.[19]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Proglycem- diazoxide suspension". DailyMed. 19 July 2024. Retrieved 28 March 2025.
  3. ^ a b c Page Module:Citation/CS1/styles.css has no content."Vykat XR- diazoxide choline tablet, film coated". DailyMed. 26 March 2025. Retrieved 17 April 2025.
  4. ^ a b c d e f g h Page Module:Citation/CS1/styles.css has no content."Diazoxide Monograph for Professionals". Drugs.com. Retrieved 11 October 2019.
  5. ^ a b Page Module:Citation/CS1/styles.css has no content.Doyle ME, Egan JM (March 2003). "Pharmacological agents that directly modulate insulin secretion". Pharmacological Reviews. 55 (1): 105–131. doi:10.1124/pr.55.1.7. PMID 12615955. S2CID 11121340.
  6. ^ Page Module:Citation/CS1/styles.css has no content."Soleno Therapeutics Announces U.S. FDA Approval of Vykat XR to Treat Hyperphagia in Prader-Willi Syndrome" (Press release). Soleno Therapeutics. 26 March 2025. Retrieved 28 March 2025 – via GlobeNewswire.
  7. ^ Page Module:Citation/CS1/styles.css has no content.World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  8. ^ Page Module:Citation/CS1/styles.css has no content.British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 708. ISBN 978-0-85711-338-2.
  9. ^ Page Module:Citation/CS1/styles.css has no content.van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT (August 1996). "Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?". Journal of Hypertension. 14 (8): 1041–1045. doi:10.1097/00004872-199608000-00016. PMID 8884561. S2CID 3283469.Closed access icon
  10. ^ Page Module:Citation/CS1/styles.css has no content.Huang Q, Bu S, Yu Y, Guo Z, Ghatnekar G, Bu M, et al. (January 2007). "Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase". Endocrinology. 148 (1): 81–91. doi:10.1210/en.2006-0738. PMID 17053028.Open access icon
  11. ^ Page Module:Citation/CS1/styles.css has no content.Randle JC, Biton C, Lepagnol JM (November 1993). "Allosteric potentiation by diazoxide of AMPA receptor currents and synaptic potentials". European Journal of Pharmacology. 247 (3): 257–265. doi:10.1016/0922-4106(93)90193-D. PMID 8307099.Closed access icon
  12. ^ Page Module:Citation/CS1/styles.css has no content.Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, et al. (April 1989). "Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets". Biochemical Pharmacology. 38 (8): 1217–1229. doi:10.1016/0006-2952(89)90327-4. PMID 2650685.
  13. ^ Page Module:Citation/CS1/styles.css has no content."FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide)" (Press release). U.S. Food and Drug Administration (FDA). 16 July 2015. Archived from the original on 19 July 2015. Retrieved 19 July 2015.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S (May 2012). "Minoxidil use in dermatology, side effects and recent patents". Recent Pat Inflamm Allergy Drug Discov. 6 (2): 130–136. doi:10.2174/187221312800166859. PMID 22409453. Other potassium channel openers, like diazoxide [39, 40] and pinacidil [41] can cause hypertrichosis in humans as well as minoxidil. In balding macaques minoxidil, cromakalin and P-1075 (a pinacidil analogue) stimulate hair growth in about 20 weeks of topical treatment, whereas a fourth potassium channel opener, called RP49356, is not effective [42].
  15. ^ Page Module:Citation/CS1/styles.css has no content.Buhl AE, Conrad SJ, Waldon DJ, Brunden MN (July 1993). "Potassium channel conductance as a control mechanism in hair follicles". J Invest Dermatol. 101 (1 Suppl): 148S–152S. doi:10.1111/1523-1747.ep12363290. PMID 8326149. The evidence that [potassium channel openers (PCOs)] are active on hair growth is correlative. In humans three PCOs have been reported to affect hair growth. Minoxidil was reported to induce hypertrichosis during early clinical trials as an antihypertensive [12]. These side effects were characterized by increasingly visual facial hair, thickening of eyebrows, and diffuse hair growth across the upper back and limbs. Systemic minoxidil induced hypertrichosis in 80–100% of adults [13]. Clinical trials using topical minoxidil demonstrate increased scalp hair in about 39% of treated balding men. Oral diazoxide causes hypertrichosis in most hypoglycemic children and about 1% of adults, and induces some scalp hair in 25% of the balding patients [13–15]. Systemic pinacidil induces hypertrichosis in 2–13% of patients [13]. We are not aware of any topical hair growth trials using pinacidil.
  16. ^ Page Module:Citation/CS1/styles.css has no content.Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. (February 2024). "Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study". Obesity. 32 (2): 252–261. doi:10.1002/oby.23928. hdl:10044/1/107689. PMC 12181816. PMID 37919617. S2CID 264973612.
  17. ^ Page Module:Citation/CS1/styles.css has no content.Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM (23 September 2019). "A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome". PLOS ONE. 14 (9) e0221615. Bibcode:2019PLoSO..1421615K. doi:10.1371/journal.pone.0221615. PMC 6756513. PMID 31545799.
  18. ^ Page Module:Citation/CS1/styles.css has no content.Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. (June 2023). "Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial". The Journal of Clinical Endocrinology and Metabolism. 108 (7): 1676–1685. doi:10.1210/clinem/dgad014. PMC 10271219. PMID 36639249.
  19. ^ Clinical trial number NCT05532020 for "An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities" at ClinicalTrials.gov

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Ionotropic glutamate receptor modulators Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Diazoxide&oldid=885766"